Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04852523 · ClinicalTrials.gov registry record · Early Phase 1

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

A Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection, sponsored by University of Utah.

Completed
Registry status
Early Phase 1
Development phase
4
Enrollment target
1
Study location

NCT04852523 is a Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection that has completed, run by University of Utah. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04852523, a Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection, has completed, sponsored by University of Utah.

COMPLETED
Registry status
Early Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function

Interventions

  • DRUG 18F-fluciclovine

Study Locations (1)

Utah

  • University of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2021-09-16
Est. Completion 2022-10-06
Phase Early Phase 1

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT04852523

The ClinicalTrials.gov registry entry for NCT04852523 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatitis, Graft appearing as the primary indexed condition, and to 1 intervention - of which 18F-fluciclovine is the first listed.

NCT04852523 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT04852523 about?

NCT04852523 is a clinical study titled "18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants". Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake ...

What is the current status of trial NCT04852523?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-09-16. Estimated completion is 2022-10-06.

What conditions does trial NCT04852523 study?

This clinical trial studies the following conditions: Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection.

What interventions are being tested in trial NCT04852523?

The interventions under investigation include: 18F-fluciclovine (DRUG).

Who is sponsoring clinical trial NCT04852523?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04852523 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.